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Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and 
morbidity worldwide, with high and growing prevalence. Its underdiagnosis and hence under-
treatment is a general feature across all countries. This is particularly true for the mild or early 
stages of the disease, when symptoms do not yet interfere with daily living activities and both 
patients and doctors are likely to underestimate the presence of the disease. A diagnosis of COPD 
requires spirometry in subjects with a history of exposure to known risk factors and symptoms. 
Postbronchodilator forced expiratory volume in 1 second (FEV
1
)/forced vital capacity ,0.7 or 
less than the lower limit of normal confirms the presence of airflow limitation, the severity of 
which can be measured by FEV
1
% predicted: stage 1 defines COPD with mild airflow limitation, 
which means postbronchodilator FEV
1
 $80% predicted. In recent years, an elegant series of 
studies has shown that “exclusive reliance on spirometry, in patients with mild airflow limitation, 
may result in underestimation of clinically important physiologic impairment”. In fact, exercise 
tolerance, diffusing capacity, and gas exchange can be impaired in subjects at a mild stage of 
airflow limitation. Furthermore, growing evidence indicates that smokers without overt abnormal 
spirometry have respiratory symptoms and undergo therapy. This is an essential issue in COPD. 
In fact, on one hand, airflow limitation, even mild, can unduly limit the patient’s physical activity, 
with deleterious consequences on quality of life and even survival; on the other hand, particularly 
in younger subjects, mild airflow limitation might coincide with the early stage of the disease. 
Therefore, we thought that it was worthwhile to analyze further and discuss this stage of “mild 
COPD”. To this end, representatives of scientific societies from five European countries have 
met and developed this document to stimulate the attention of the scientific community on COPD 
with “mild” airflow limitation. The aim of this document is to highlight some key features of this 
important concept and help the practicing physician to understand better what is behind “mild” 
COPD. Future research should address two major issues: first, whether mild airflow limitation 
represents an early stage of COPD and what the mechanisms underlying the evolution to more 
severe stages of the disease are; and second, not far removed from the first, whether regular 
treatment should be considered for COPD patients with mild airflow limitation, either to prevent 
progression of the disease or to encourage and improve physical activity or both.
Keywords: chronic obstructive pulmonary disease, COPD, airflow limitation, COPD staging, 
GOLD document, COPD pathophysiology
Background and aim
Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and 
morbidity worldwide,1,2 with high and growing prevalence regionally and globally.3 
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A recent review suggests that there is a trend of decreas-
ing mortality for COPD in men, whereas it is increasing in 
women.4 Its underdiagnosis and hence undertreatment is a 
general feature across all countries.5 This is particularly true 
for the mild or early stages of the disease, when symptoms 
may not yet interfere with daily living activities, and both 
patients and doctors are likely to underestimate the presence 
of the disease.
A diagnosis of COPD requires spirometry in subjects 
with a history of exposure to known risk factors, cigarette 
smoking in particular, and such symptoms as dyspnea and/or 
chronic cough with sputum production. Postbronchodilator 
forced expiratory volume in 1 second (FEV
1
)/forced vital 
capacity (FVC) ,0.7 or below the lower limit of normal 
(LLN) confirms the presence of persistent airflow limitation, 
the severity of which can be assessed by means of the value 
of FEV
1
% predicted: the stage/grade 1 defines COPD with 
mild airflow limitation, which means postbronchodilator 
FEV
1
 $80% predicted.1
The recent GOLD (Global Initiative for Chronic Obstruc-
tive Lung Disease) document, though recognizing some 
“imperfection” of that choice, confirms the postbroncho-
dilator FEV
1
:FVC ,0.7 criterion for the diagnosis of per-
sistent airflow limitation for its diagnostic simplicity and 
consistency. Adoption of the LLN values, as recommended 
by the European Respiratory Society–American Thoracic 
Society task force on lung-function tests,6 would be even 
more “imperfect”, according to the GOLD document, due to 
biases caused by age, height, and sex differences.1 However, 
a prospective comparison between both spirometric criteria 
and an expert-based diagnosis of COPD concluded that 
the fixed ratio and the LLN overestimated and underes-
timated, respectively, the presence of COPD in elderly 
subjects;7 the authors recommended incorporation of FEV
1
 
and residual volume (RV)/total lung capacity (TLC) in the 
COPD definition.7 A new approach to normal spirometry was 
provided by the Global Lung Initiative (GLI), a European 
Respiratory Society task force, which made available a 
spirometric prediction equation for the age-group 3–95 years 
applicable to different ethnic groups (Caucasian, African-
American, Asian).8 Z-scores were calculated for spirometric 
variables and compared to fixed-ratio data, suggesting that 
the FEV
1
:FVC ,0.7 ratio would misclassify individuals, 
with GLI-defined normal spirometry, as having respira-
tory impairment.9,10 Quanjer et al recommend the use of 
the GLI equations8 coupled with standardization in testing 
methodology11 for interpretation of spirometry free of major 
sources of bias.12
Although other factors, such as symptoms, exacerbations, 
complications, and comorbidities, are considered in clas-
sification of the overall severity of the disease,1 spirometry 
remains a cornerstone, at least for the initial evaluation. 
Probably most patients with mild airflow limitation fit the 
A category of new GOLD staging, but in more infrequent 
cases patients with mild COPD may be classified in any of 
the new GOLD categories, A–D.1
In recent years, an elegant series of studies showed that 
“exclusive reliance on spirometry, in COPD patients with 
mild airflow limitation, may result in underestimation of 
clinically important physiologic impairment”.13 This is 
an essential issue in COPD. In fact, on one hand, airflow 
limitation, even mild, can unduly limit the patient’s physical 
activity;14,15 on the other hand, particularly in younger 
subjects, mild airflow limitation might coincide with the early 
stage of the disease.16,17 In this connection, it is worthy of 
note that the mean age of COPD patients does not differ very 
much among stages, from mild to severe and very severe, in 
large trials18 or observational19,20 and physiologic studies.21,22 
This suggests that in some subjects, mild airflow limitation 
might be the only physiologic phenotype of the disease, 
while in others it could represent the first stage toward a 
progressive deterioration in lung function. Therefore, we 
thought it worthwhile to analyze further and discuss this 
stage of “mild COPD”.23
To this end, representatives of scientific societies from 
five European countries have met and developed this docu-
ment to stimulate the attention of the scientific community 
on COPD with “mild” airflow limitation. The aim of this 
document is to highlight some key features of this important 
concept and help the practicing physician to understand better 
what is behind “mild” COPD.
It has been known for many years that smokers, with 
relatively preserved FEV
1
 and conventional spirometry within 
normal limits, may have extensive small-airway impairment, 
eg, hypersecretion and inflammation,24–26 with physiologic 
abnormalities, which can be measured by means of adequate 
physiologic tests and are not detectable in otherwise healthy 
nonsmokers.14,27–30 Pathologic abnormalities in the periphery 
of the lungs not yet detectable with spirometry may explain 
the growing prevalence of symptomatic smokers, even 
requiring pharmacologic treatment, with spirometry still 
within the normal limits.31,32 A simplified view of the natural 
history of COPD might assume that small-airway disease 
in smokers can progress to mild airflow limitation, which 
deteriorates to moderate and severe lung-function impair-
ment and eventually respiratory failure. Unfortunately, this 
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attractive hypothesis has not yet received sufficient experi-
mental support from longitudinal surveys.
In 1977, Fletcher and Peto showed that there is a group 
of susceptible smokers with an enhanced decline in lung 
function with age.33 Despite well-known methodological 
limitations,34 this seminal study has constituted the reference 
model for our understanding of the natural history of COPD 
for the past 40 years. Recent research, however, has shown 
that it does not reflect reality accurately.35 On one hand, accel-
erated loss of lung function is not present in 40% of patients 
diagnosed and treated for COPD;36 on the other, a number 
of potential factors, such as the effect of lung development 
during childhood and adolescence,37,38 the role of bronchial 
hyperresponsiveness, and/or the role of infection, among 
others, can influence the risk of developing the disease or 
its progression with time from early stages.39
In this context, it is important to reiterate that “mild 
disease” is not necessarily synonymous with “early disease”.16 
The latter refers to an initial time point during the course of 
the disease. Young age is a natural surrogate of early disease; 
by contrast, the former refers to the severity of the disease, 
which may be independent of age, eg, a 75-year-old patient 
with mild airflow limitation.
Little is known about the early stages of COPD,16,17,39 
because most patients are either not diagnosed or diagnosed 
at the age of 60/70 years, when they have already developed 
moderate–severe disease. Population studies, such as the 
European Community Respiratory Health Survey (ECRHS)40 
and the EPISCAN in Spain,41 estimated a prevalence of 
COPD in the age-group 40–49 years of 3.6% and 3.8% 
(4.4% in men and 3.2% in women), respectively. Further-
more, in both studies, the diagnosis of COPD was associated 
with poorer quality of life and greater use of health resources. 
Clearly, the presence of mild airflow limitation at the age 
of 50 years or less has greater clinical relevance than at the 
age of 70 years.
The clinical/biological determinants of progression 
from early COPD are unclear. Some studies indicate that 
the majority of patients in GOLD grade 1 (recognizing that 
this may not necessarily mean early COPD, but mild airflow 
limitation) do not develop clinically significant COPD, even 
if the person continues smoking.42 Other studies report that 
lung-function decline is faster in the mild–moderate stages 
of the disease,43,44 mainly among symptomatic patients,45 
and in patients who have recurrent lower respiratory tract 
infections and continue to smoke.46 Furthermore, it has been 
demonstrated that exacerbations accelerate the loss of lung 
function more in patients with mild than with severe COPD.47 
Also of interest is the association of COPD grade 1 with other 
diseases. It has been reported that patients in GOLD grade 1 
(mild airflow limitation, but not necessarily early disease) 
have a threefold risk to develop depression48 or increased 
risk of lung cancer49 than healthy controls.
Biomarkers of disease activity/progression in early COPD 
are unknown. Recently, CC16,50 SPD,51 and a battery of six 
markers of persistent systemic inflammation52 have been 
proposed as biomarkers of disease progression. However, 
none of them has been studied in COPD patients with mild 
airflow limitation, and other potential markers of progres-
sion, such as changes in the microbiome or genetic factors, 
have not been explored. Since several pathogenic processes 
could be active in the same individual, these processes can 
be present at different times in the individual patient.16
Epidemiology
Many epidemiological surveys have documented the high 
prevalence of COPD in the general adult population, in 
both men and women. In fact, the prevalence is consistently 
higher in men, and rises with age. Clearly, COPD is much 
more frequent in smokers and ex-smokers, but with a con-
tribution also from never-smokers. Most publications report 
the data organized by age-groups and smoking habits, not 
by stages of severity. However, few studies have provided 
the classification of the COPD population according to the 
GOLD 2007 stages of airflow limitation.53
The BOLD epidemiological research reports data on 
9,425 men and women from 12 countries worldwide. 
The diagnosis of COPD was based on postbronchodila-
tor FEV
1
:FVC ,0.7.54 Overall, the prevalence of airflow 
limitation in the different countries ranged from 11.3% 
to 26%, increasing consistently through age-groups from 
40 to .70 years. Grade 2 or more averaged 11.8% and 8.5% 
in men and women, respectively. The prevalence of grade 1 
ranged from 1.4% to 15.5%, with an average of 8.1%, being 
6.7% and 9.6% in women and men, respectively. A sub-
sequent analysis focused on the difference between ever-
smokers (5,709) and never-smokers (4,291). Overall, 12.2% 
never-smokers fulfilled the criteria for GOLD COPD, 6.6% 
being classified as GOLD 1. Furthermore, never-smokers 
made up 27.7% of all COPD cases and 33% of GOLD 1. 
GOLD 1 amounted to 8.3% of cases in men and 5.7% in 
women. These data show that COPD with mild airflow limita-
tion is a real issue in the COPD population, and in particular 
among never-smokers.55
In the Spanish investigation on 4,274 adults aged 
40–80 years, 3,802 subjects underwent good-quality 
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postbronchodilator spirometry.41 The overall prevalence 
of airflow limitation was 10.2%, 15.1% in men, and 5.6% 
in women, and 7.1% and 2% in GOLD 2–4 respectively, 
increasing with age and smoking habits. COPD prevalence 
by GOLD classification of severity gave the following results: 
mild 56.4%, moderate 38.3%, severe 4.6%, and very severe 
0.5%. The ECRHS study on more than 18,000 young adults 
(20–44 years) from 35 sites in 16 “high-income” countries 
showed stage 1 and stage 2–4 prevalence of 2.5% and 
1.1%, respectively,40 with an overall prevalence of COPD 
amounting to 3.6%. The diagnosis of airflow limitation was 
obtained with spirometric measurement of prebronchodila-
tor FEV
1
:FVC ,0.7. Both the BOLD and the ECRHS sur-
veys showed a remarkable difference in prevalence among 
countries. In the COPDGene cross-sectional observational 
study on 9,000 subjects, 9% were classified as GOLD 1, 
with a mean age of 61 years, slightly lower and higher than 
GOLD 2–4 and GOLD 0, with average mean ages of 63 and 
56 years, respectively.32
A crucial issue is whether COPD patients with mild airflow 
limitation sought contact with doctors. The Italian survey on 
COPD showed that 18.2% of the about 4,000 COPD patients 
referred to pulmonary clinics in Italy had mild airflow limita-
tion and that 86% received some pharmacologic treatment 
(long-acting bronchodilators and/or inhaled corticosteroids).19 
However, the prevalence of reported exacerbations and 
comorbidities was 44.5% and 64%, respectively, the latter 
not far from the 81% of patients with very severe airflow 
limitation. This study suggests that COPD patients with 
mild airflow limitation are likely to seek doctors and even 
pulmonologists more for exacerbations and/or comorbidities, 
rather than common respiratory symptoms, such as dyspnea 
or cough. However, the ECLIPSE study18 reported that the 
majority of COPD patients with moderate–severe airflow 
limitation were not frequent exacerbators. In fact, the 2-year 
follow-up data from the DACCORD study20 showed that in 
a population of COPD patients with a low rate of exacerba-
tion (,0.4 exacerbations/year), respiratory symptoms were 
a common cause for seeking medical help and should not 
be underestimated, as a significant improvement can be 
obtained with pharmacologic treatment. In the DACCORD 
population, almost 20% had mild airflow limitation.20 In 
the longitudinal results from the COPDGene study47 48 of 
185 COPD patients classified as GOLD 1 were receiving 
pharmacologic treatment with long-acting bronchodilators 
and/or inhaled corticosteroids at the 5-year visit.
Lange et al56 compared the mortality rate between the 
old (2007)53 and the new (2011)1,57 GOLD classifications 
on 6,628 individuals with COPD in the Copenhagen study. 
Among the 3,306 (50% of the total) patients with GOLD 1 
airflow limitation, 90% were classified as A, whereas 10% 
were classified as B, C, and D, ie, patients with symptoms 
and exacerbation risk. In that study, women were 54%, and 
never-smokers 26% in GOLD stage 1. Mortality averaged 
0.7% and 4% after 1 and 3 years, respectively, compared to 
2.2% and 25.8% in GOLD 2007 stage IV patients.
In Slovenia, the National Institute of Public Health (NIJZ) 
is a state institution that reports prevalence of diseases on 
national level. In the Supplementary material, data from 2008 
are presented for a small region of northern Slovenia (with 
high prevalence of smoking, above the average Slovenian 
level). The striking finding is the high prevalence of smoking 
in younger adults, which is increasing mostly in young 
women. Overall prevalence of COPD in that region is 5.7%, 
and in smokers 16.6%.
Pathology
There is consensus on the notion that in COPD, inflammation 
in the small airways is related to cigarette smoking. However, 
the hypothesis of a central role of small-airway inflammation 
in the pathogenesis of COPD has been challenged by many 
recent studies. The role of premature lung aging has been 
proposed by many authors as central in the pathogenesis 
of COPD,58–60 where the critical balance between senescence 
and antisenescence factors is disrupted toward senescence in 
COPD lungs.61–66 Telomere attrition is anticipated in COPD 
lungs, and this view is further supported by the occurrence 
of relevant comorbidities, such as weight loss, osteoporosis, 
cardiovascular diseases, and depression, all conditions where 
premature senescence and telomere-length abnormalities 
have been documented.65 Experimental studies have dem-
onstrated that telomere length is a susceptibility factor in 
emphysema.66–68
The parenchymal remodeling and progressive dilation of 
alveolar spaces that is observed in emphysema is likely related 
to decreased and/or deregulated production of extracellular-
matrix proteins, with eventual impaired capability to sustain 
connective and epithelial tissue repair. Several studies have 
evidenced connective tissue insufficiency leading to pro-
gressive decrease of matrix-protein production.66 Premature 
stem-cell exhaustion can represent the best candidate for 
this putative pathogenic mechanism. Senescence-related 
markers in COPD are mainly demonstrable in mesenchymal 
cells (fibroblasts and endothelial cells),68 and a large variety 
of abnormalities have been described affecting pulmonary 
mesenchymal precursors, fibroblasts, and endothelial cells in 
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both human and experimental COPD.69–73 Notch and Wnt are 
signaling pathways involved in the correct differentiation of 
mesenchymal precursors.74–77 Insufficient local immunoregu-
lation might explain the autoimmune-like chronic inflamma-
tion and damage of small airways in COPD.61,78
Pathophysiology
Knowledge of the pathophysiology of COPD with mild 
airflow limitation is essential to understand the changes 
taking place in the lungs before the development of more 
severe spirometric abnormality, ie, GOLD $2.1,53,57 We can 
distinguish three levels: level 1, in which the biologic and 
physiologic abnormalities in the small airways of smokers 
coexist with spirometric values within normal limits;14 
level 2, COPD with mild airflow limitation (GOLD 2007 
stage 1);53 and level 3, COPD with moderate–severe and very 
severe airflow limitation (GOLD 2007 stage 2–4).53,79
In level 1 (small-airway disease), pathobiological changes 
in the lungs can be detected by means of tests of small-airway 
function, which disclose abnormalities not present in healthy 
nonsmokers.80 The single-breath nitrogen-washout test exhib-
its a high nitrogen slope of the alveolar plateau (N
2
 slope, 
phase III), closing volume, and closing capacity.29,81,82 Among 
the tests that detect small-airway disease,83–86 one of the 
most sensitive (yet not in widespread use) appears to be 
low-density spirometry,86 ie, assessing spirometric maximal 
expiratory flow volume before and after inhalation of heliox. 
The aforementioned tests are sufficiently sensitive indicators 
to allow detection of small-airway obstruction in smokers 
at a stage when the maximal expiratory flow-volume curve 
(while breathing air) is within normal limits.82 The majority 
of smokers (87%) who developed abnormal FEV
1
 during a 
9- to-11-year follow-up had an abnormal single-breath N
2
 
test at some time prior to their FEV
1
 becoming abnormal.84 
However, the positive predictive value of an abnormal 
single-breath N
2
 test is quite low, in that a large proportion 
of smokers with an abnormal single-breath N
2
 test do not 
progress to abnormal FEV
1
.29,84 Recently, Elbehairy et al 
demonstrated that current symptomatic smokers who did 
not meet the spirometric criteria for an overt diagnosis of 
COPD had lower exercise tolerance, higher neuromuscular 
drive, and greater diaphragmatic effort than comparable 
healthy controls.14
It has been shown that pathologic abnormalities in the 
small airways were found in COPD patients with mild airflow 
limitation.25,60 Smokers with mean FEV
1
:FVC of 0.717±0.038 
but with small-airway disease detected by single-breath 
N
2
-washout test have reduced FEV
1
, and thus may be more 
susceptible to long-term smoking than smokers without 
small-airway disease to develop overt COPD.87 In smok-
ers with airflow limitation (mean FEV
1
:FVC 0.597±0.06), 
an abnormal single-breath N
2
-washout test predicted the 
development of low FEV
1
 13 years later.29 Patients with 
mild COPD may exhibit resting lung hyperinflation with 
increases in functional residual capacity (FRC; 119%–121% 
predicted) and RV (129%–135% predicted).88,89 Mid-volume 
expiratory-flow rates are also reduced (forced expiratory 
flow 25%–75% and 50%).88,89 Measurement of respiratory 
resistance and impedance with the oscillatory technique 
also has the potential to assess mild COPD. Frantz et al90 
showed that pulmonary resistance measured by means of 
the impulse-oscillation system can be abnormal earlier than 
conventional spirometry.
The majority of COPD patients with mild airflow 
limitation have a reduction in lung-diffusing capacity for 
carbon monoxide (DL
CO
),91,92 though this reduction does 
not unanimously reach below 80% predicted.22,82,88,89 This 
reduction in diffusing capacity is a feature of both mild 
disease and early (and thus mild) disease.80 In fact, Harvey 
et al followed a cohort of smokers with normal spirometry 
for up to 13 years, and found that among those with low 
DL
CO
 (,80% predicted), ten (22%) of 46 developed spiro-
metric obstruction (FEV
1
:FVC ,0.7), whereas among those 
with normal DL
CO
 (~80%), only two (3%) of 59 developed 
spirometric obstruction.93 The result remained the same 
when either a fixed FEV
1
:FVC ratio (,0.7) or the LLN 
(of FEV
1
:FVC , LLN) was used.94 Therefore, it stands to 
reason that diffusion impairment may occur before spiro-
metric obstruction becomes manifest in the natural history 
of the disease.
On average, arterial blood gases are within the normal 
range in COPD patients with mild airflow limitation.22,91 
However, the alveolar–arterial O
2
-tension gradient (D
A–a
O
2
) 
is elevated (.15 mmHg) at rest and during exercise.22,91,95,96 
Ventilation–perfusion (V˙
a
:Q˙) distribution, measured by 
means of the multiple inert-gas-elimination technique in 
patients with mild airflow limitation, unravels V˙
a
:Q˙ mis-
matching, predominantly perfusion dispersion,22,95 which is 
greater than predictable from the degree of airflow limitation, 
thus suggesting that COPD initially involves the periphery 
of the lungs, ie, small airways, parenchyma, and pulmo-
nary vessels, with minimal or even negligible spirometric 
abnormalities. Recent data from the MESA study97 showed 
that pulmonary vascular blood flow was reduced in COPD 
patients with mild airflow limitation, and also in lung regions 
without obvious emphysema.
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In COPD patients with mild airflow limitation during 
exercise, minute ventilation is higher than in healthy control 
subjects at any given workload (in watts). Dyspnea, measured 
by means of the Borg scale, is greater at any level of minute 
ventilation, such that dyspnea is significantly greater at 
any given workload, and it is associated with a progressive 
decrease in inspiratory capacity, ie, dynamic hyperinflation, 
which does not occur in controls.89 Furthermore, minute 
ventilation/CO
2
 production, dead space to tidal volume ratio 
(V
D
:V
T
), and arterial to end-tidal CO
2
 difference are all higher 
than in healthy controls.91 Dynamic hyperinflation and tidal 
volume constraints result in a breathing pattern that becomes 
rapid and shallow.89,91 In those patients, the high V
D
:V
T
 leads 
to a compensatory rise in minute ventilation during exercise, 
thus maintaining effective alveolar ventilation and normal 
arterial blood gases, but at the expense of earlier dynamic 
mechanical abnormalities, greater dyspnea, and poor exercise 
tolerance.
Compared to healthy controls, subjects with mild airflow 
limitation at the highest equivalent work rate (60 W) have 
significantly higher total work of breathing, electromyo-
graphic activity of the diaphragm (EMG
di
) and EMG
di
 to 
transdiaphragmatic pressure (P
di
) ratio.92 These findings 
indicate that greater neuromuscular drive (EMG
di
) is needed 
at any given level of diaphragmatic effort (P
di
). Furthermore, 
dyspnea–ventilation slopes are significantly higher in mild 
COPD than controls. Therefore, increased inspiratory effort 
and work in breathing and wider dissociation between dia-
phragmatic activation and pressure-generating capacity are 
observed at fixed work rates in subjects with mild COPD than 
in control subjects. In line with these mechanical and neuro-
muscular abnormalities, dyspnea is greater than in controls. 
Although significant dyspnea is experienced only at higher 
exercise work rates, overall exercise tolerance is reduced 
in COPD patients with mild airflow limitation compared to 
healthy controls.
Traditionally, the impairment of cardiac function is 
regarded as a late complication of severe COPD, affecting 
the right sections of the heart, a clinical picture known as cor 
pulmonale. However, in a cardiovascular disease-free study 
population, Barr et al98 showed that subclinical hemodynamic 
changes involving the left ventricle occur with mild emphy-
sema and airflow limitation.
In summary, “mild” spirometric abnormality, or even 
normal spirometry in smokers,14 is associated with important 
physiologic disturbances that may not manifest at rest and 
generate symptoms, ie, dyspnea, only during moderate–high 
levels of exercise. This may explain why this stage of COPD 
does not attract the attention of either the patient or the doctor 
until exercise intolerance reaches a level that interferes with 
daily life activities.30
Imaging
Chest X-ray is a standard part of the clinical evaluation of 
subjects with COPD, but it lacks sensitivity in detecting 
both airway disease and mild emphysema. The utility of 
chest X-ray is limited to exclude other conditions that may 
imitate COPD or complications, such as pneumonia. By 
contrast, techniques in chest imaging and quantitative image 
analysis have advanced to the point where they can provide 
novel in vivo insight into disease and potentially examine 
divergent responses to therapy. Computed tomography (CT) 
of the chest has become the standard method used for objec-
tive visualization of the lungs in COPD. It can provide useful 
measures of emphysema, airway-wall thickening, and air 
trapping associated with the disease.32,99–101 Previous studies 
have shown that emphysema and airway-wall thickening 
on CT relate poorly to pulmonary function. The sensitivity 
of high-resolution CT in detecting early emphysema can 
be low, but its accuracy is greater than pulmonary function 
tests.100,101 The population-based study of Barr et al showed 
that significant emphysema can be detected by means of 
the thoracic CT scan in subjects with preserved spirometric 
values.98 The COPDGene study showed that 81% of GOLD 1 
and 42% of GOLD 0 patients had evidence of emphysema or 
airway disease by means of quantitative CT-scan analysis.32 
In GOLD 1 patients, 67% showed airway thickening and 
68% predominant emphysema. In GOLD 2–4 patients, 
100% had quantitative CT-scan abnormalities. Quantitative 
CT evidence of hyperinflation of the lungs predicts a rapid 
annual decline in FEV
1
 in smokers with normal FEV
1
.102 The 
ECLIPSE study showed that the prevalence of all patterns 
of emphysema clearly increased across the GOLD grades, 
and emphysema was almost universally found in GOLD 4 
patients.103 Bronchial wall thickening also increased in 
prevalence with GOLD grade, while centrilobular nodular-
ity decreased in prevalence. CT lung-density measurements 
are used for the evaluation of the degree and the distribution 
of emphysema and air-wall dimensions. An elegant study 
from Jones et al104 found a significant correlation between 
the ventilatory response to exercise (  V /V
E CO2
) and emphy-
sema severity. This in turn was related to reduced diffusing 
capacity, but not to airway-wall thickness, both assessed by 
means of CT.
Identification of the clinical, imaging, and genetic charac-
teristics of GOLD 1 subjects with progressive disease could 
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provide opportunities for early treatment interventions.105 
The COPDGene study has reported epidemiological and 
radiological characteristics (quantitative CT lung-density 
measurements) of GOLD 1 subjects. Clustering of GOLD 1 
subjects identified “near-normal”, “airway-predominant”, 
“emphysema-predominant”, and “lowest FEV
1
% predicted” 
subtypes. This study demonstrated substantial clinical hetero-
geneity of COPD patients with mild airflow limitation.105 The 
COPDGene study included 10% of GOLD 1 patients, who 
had clear abnormality of emphysema and/or small-airway 
disease at CT scan. Interestingly enough, these patients 
exhibited an FEV
1
 decline over 5 years of observation, 
which was significantly greater than in GOLD 2+ patients.99 
Furthermore, GOLD 1 subjects with positive anamnesis of 
exacerbations exhibited thicker airway walls and greater 
prevalence of chronic bronchitis than patients without exac-
erbation in the previous year.105 Although thoracic CT is a 
very powerful tool for investigating the periphery of the lungs 
and has generated many expectations for a new subclassifica-
tion of COPD, it has not yet achieved success comparable 
with that obtained by high-resolution CT for interstitial lung 
diseases.106 Other imaging modalities are interesting tools 
for ascertaining the mild stages of COPD, but are far from 
influencing clinical practice.16
Clinical
Dyspnea is the most common symptom for which COPD 
patients seek medical advice. However, in patients with 
mild airflow limitation, dyspnea is perceived mainly with 
moderate–high levels of exercise, rather than at rest.13,89 
Most COPD patients are smokers or aged ex-smokers, and 
hence they accept symptoms as direct consequences of both 
smoking and aging. Most often, patients choose to limit 
their physical activities to avoid the gradually emerging 
dyspnea on exertion. They often do not ask for medical care 
until the symptoms interfere with their daily life activity, 
which typically occurs in more severe disease. However, 
there is also a group of patients with slightly abnormal 
spirometry who are otherwise asymptomatic. Exercise-
induced shortness of breath is one of the earliest COPD 
symptoms, progressing over the course of the disease 
and often determining a significant reduction in activity 
levels, which in turn may cause deconditioning, skeletal 
muscle dysfunction, and further functional limitations.107 
Recent studies have demonstrated muscle weakness of arms 
and legs in GOLD 1 patients, documenting that physical 
deconditioning is present in COPD patients with mild 
airflow limitation.107,108
Chronic bronchitis, ie, cough and sputum on most days 
for 3 consecutive months in 2 consecutive years, is frequent 
in smokers, and can be present with mild airflow limitation 
and even without airflow limitation, but it is associated with 
poorer health status and worse prognosis.109,110 The tradi-
tional physical examination is often negative in most COPD 
patients with mild airflow limitation.
Patients with mild airflow limitation are not a homo-
geneous group. Symptomatic patients have a faster rate of 
decline of lung function, lower health-related quality of life, 
and increased health utilization compared with asymptom-
atic individuals.107 Recent research has indicated that health 
care utilization and health-related quality of life are similar 
in asymptomatic patients with mild airflow limitation and 
in those with normal lung function.111 On the other hand, 
some patients have significant symptoms with near-normal 
lung function.14 This could be attributed to excessive venti-
latory demand with decreased inspiratory muscle pressure- 
generating capacity due to dynamic hyperinflation, and 
ventilation–perfusion mismatching during exercise.107
Although COPD exacerbations are usually associated 
with more severe disease, they can occur in patients with 
GOLD 1 stage. In a 1-year prospective study, 70% of patients 
with mild and moderate airflow limitation (FEV
1
 $50% 
predicted) reported at least one exacerbation.111 In the 
COPDGene study,47 27.4% of GOLD 1 patients experienced 
one or more exacerbations during the 5 years of observa-
tions with a mean rate/year of 0.18 compared to 0.13 of 
GOLD 0 and 0.89 of GOLD 4 patients, respectively. In an 
Italian observational study on about 4,000 COPD patients, 
745 were classified as GOLD 1; only 55% reported being 
exacerbation-free, and 20% reported two or more exacerba-
tions in the previous year, with 9.6% reporting one or more 
hospitalizations.19 A survey of 3,306 COPD patients classified 
as GOLD 1 showed that about 10% were in categories B, 
C, and D of the 2011 GOLD classification, suggesting that 
they had symptoms. About 1% were classified as C and D, 
also indicating a high risk of exacerbation.54 In the GOLD 
1 group, 2.5% of the mild group had exacerbations in the 
previous year. In the 3 years of observation, the average 
number of exacerbations per year was 0.1, with 27 hospital 
admissions due to COPD and two respiratory deaths, while 
deaths from any causes increased from 4% to 5.9%, 14.3%, 
and 25.8% from stage 1 to 4.
In fact, the actual incidence of exacerbations in COPD 
with mild airflow limitation may be higher than expected, 
since many are likely to be unreported.107 In a study of 
patients with GOLD 1, the incidence of acute events was 
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higher (1.8 episodes per year) than in controls (1.4 episodes 
per year).112 It has been documented that the occurrence of 
exacerbations is associated with faster loss of lung function 
in GOLD 1 and 2.33
The overall burden of COPD is aggravated by comorbidi-
ties, which are often observed early in the disease progression. 
These include diabetes, cardiovascular disease, osteoporosis, 
gastroesophageal reflux, and depression. In the Italian sur-
vey, the presence of at least one comorbidity was reported 
by 64% of GOLD 1 patients compared to 81% of patients 
classified as GOLD 4.19 Patients with COPD are at greater 
risk of developing depression than demographically matched 
healthy controls, even at the mild stages of the disease. The 
ECLIPSE study reported that comorbidities were independent 
of severity of airflow limitation.113 However, in the German 
observational study, including almost 70% grades 1 and 2 
COPD, the exacerbation rate was low, and such symptoms 
as dyspnea had a major impact on patients’ lives.20
In conclusion, COPD patients with mild airflow limitation 
are likely to seek medical help more for different reasons, 
such as exacerbations, dyspnea, and comorbidities. In 
particular, however, episodes of mild exacerbation should 
draw the attention of the attending physician to a more 
complete evaluation of the patient’s condition and to plan a 
follow-up program.
Physical activity
Particular attention should be devoted to the issue of physi-
cal activity in COPD patients with mild airflow limitation. 
Although specific studies on this subgroup of patients are 
lacking, several lines of evidence have shown that physi-
cal activity is consistently low in COPD patients at any 
stage,114 with deleterious consequences on decline in lung 
function,115 extrapulmonary effects,116 quality of life, and 
even survival.117,118 The mechanisms of interaction between 
physical (in)activity and the pathophysiology of chronic 
disorders is poorly understood, and certainly deserves 
future research.15 Rehabilitation programs give inconsistent 
results on physical activity, although sometimes the effect 
of rehabilitation is statistically significant.119 However, due 
to the beneficial effects, including the increased survival120, 
of physical activity in human beings, behavioral changes 
to a more active life, in addition to smoking-cessation 
programs, should be encouraged at any stage of airflow 
limitation.15
Therapy
The treatment of COPD patients cannot be “one size fits 
all”. The overall assessment of the disease must include 
measurements of lung function and symptoms, as well as 
estimation of exacerbations and comorbidities.1 It has been 
suggested that it might be possible to link the therapy to the 
patient’s phenotype,120–122 and this concept deserves further 
investigation.18,52,100,123,124 However, although it does not 
reflect either the severity of the overall disease57,125 or the 
total impairment in lung function,126 the measurement of the 
FEV
1
% predicted remains a milestone variable in all clinical 
trials in COPD.
Traditionally, clinical trials on COPD therapy have 
recruited patients with postbronchodilator FEV
1
:FVC ,0.7 
and FEV
1
 ,80%, thus excluding patients with mild airflow 
limitation.19,77,125,127 However, real-life studies have shown 
than not only patients with mild airflow limitation are 
treated20 and even over-treated19,21 but also that symptomatic 
subjects with normal spirometry receive prescriptions of 
bronchodilators and inhaled corticosteroids.14,31,32 The only 
study specifically addressing GOLD 1 patients was that done 
by O’Donnell et al,128 who performed a short-term, random-
ized, double-blind, placebo-controlled, crossover clinical trial 
in COPD patients with mild airflow limitation, measuring 
lung function and exercise tests after either placebo or the 
nebulizer ipratropium bromide 500 μg. Interestingly, the 
mean baseline modified Medical Research Council dyspnea-
scale score was .1, suggesting the presence of symptoms 
even with postbronchodilator FEV
1
 averaging 90% predicted. 
Mean postbronchodilator FEV
1
:FVC was ,0.6, and lung 
volumes showed a slight degree of lung hyperinflation, while 
DL
CO
 and maximum pressures were well within the normal 
limits, while airway resistance increased. Symptom-limited 
V
O2
 averaged 1.8 L/min, ie, 79% predicted. O’Donnell et al128 
found that treatment with a short-acting bronchodilator, 
ie, ipratropium bromide, was associated with a significant 
improvement in FEV
1
, airway resistance, and RV. During 
exercise, there was a significant increase in dynamic inspira-
tory capacity, though there was no improvement in endurance 
time. The reduction in dynamic hyperinflation was linked to a 
reduction in ratings of exertional dyspnea intensity at higher 
levels of ventilation. The authors suggested that this study 
provided a physiologic rationale for considering a trial of 
bronchodilating therapy in COPD patients with mild airflow 
limitation who experience activity-related dyspnea. Casaburi 
et al129 investigated the effect of tiotropium on pulmonary 
hyperinflation and exercise tolerance in symptomatic patients 
with mild–moderate airflow limitation (GOLD 1 and 2).53 
In that 22-week, randomized, crossover study, they found 
that tiotropium improved inspiratory capacity in both groups 
of GOLD 1 and 2 patients, whereas exercise duration was 
enhanced only in group 2 (moderate airflow limitation). 
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The lack of effect of tiotropium on exercise tolerance, despite 
the significant reduction in dynamic lung hyperinflation in 
GOLD 1, was only partially explained by a limitation of the 
study protocol. Additional research on GOLD 1 patients 
was encouraged.
A few studies in the 90s recruited COPD patients with 
mild–moderate airflow limitation in prospective trials. The 
longest period of observation, 11 years, was obtained in the 
Lung Health Study on smoking cessation,130 which showed 
that smoking cessation was effective to slow FEV
1
 decline 
significantly and quite substantially in sustained quitters com-
pared to intermittent quitters and continuous smokers, par-
ticularly in COPD with mild airflow limitation.46 By contrast, 
three prospective clinical trials, lasting 4131 and 3132,133 years, 
failed to show any effect of inhaled corticosteroids in the rate 
of FEV
1
 decline in patients with mild–moderate COPD. In 
the Copenhagen study,132 mean FEV
1
 was .80% predicted, 
suggesting a high proportion of patients with mild rather 
than moderate COPD. That study failed to find any effect of 
budesonide on symptoms and exacerbations. An interesting 
observation in EUROSCOPE133 was the FEV
1
 improvement 
in the budesonide group (+17 mL on average) and not in the 
placebo group (-81 mL on average) in the first 6 months 
of the study. Afterward, the decline progressed at a similar 
rate from the 9th month to the end of treatment. A 5-year 
follow-up clinical trial compared the effect of inhaled ipratro-
pium with placebo, and an aggressive smoking-intervention 
program, in COPD patients with mild–moderate airflow 
limitation: the use of the bronchodilator did not influence 
the long-term decline in FEV
1
.134
On the basis of the available evidence, it may be con-
cluded that in COPD patients with mild airflow limitation:
•	 smoking cessation is the most effective measure to 
decrease the rate of FEV
1
 decline;
•	 changes in lifestyle toward more active physical activity 
must be encouraged;
•	 a short-acting muscarinic antagonist can improve lung 
function, at least in the short run, but influences the rate 
of FEV
1
 decline;
•	 regular monotherapy with inhaled corticosteroids does 
not reduce either the rate of decline of FEV
1
 or the rate 
of exacerbations; however, a rich body of data in a recent 
publication suggests that a substantial proportion of 
patients with COPD may not have rapid FEV
1
 decline, 
which for decades has been regarded as the hallmark 
of COPD.135
The last point has important implications for future 
research on mild COPD. In fact, it suggests that different end 
points should be considered to assess the effect of treatments 
on the progression of the disease, eg, other tests of lung 
function, exacerbations, quality of life, and symptoms.31,47
Pulmonary function tests
In this document, we are not addressing the investigation of 
lung function in smokers, either with or without symptoms, 
with spirometry within normal limits and possibly small-
airway disease.14,31 Furthermore, we are not addressing the 
longstanding question of whether a fixed FEV
1
:FVC ,0.7 
or ,LLN ratio should be preferred;1 nor are we debating 
whether FVC or VC should be the denominator.125 However, 
the GLI approach8,12 is discussed in this article because it may 
be a major topic of future research. For this article, we accept 
the operational definition adopted in most articles on patients 
with a diagnosis of COPD and mild airflow limitation.53,89 
However, on the basis of the available evidence, we recom-
mend some additional physiologic measurements, which 
may provide a better understanding of lung abnormalities, 
in particular in patients with such symptoms as dyspnea14,31 
and/or chronic cough and sputum.136
Lung volume
TLC is needed to distinguish between a true obstructive 
pattern (TLC within normal limits or above LLN) or a mixed 
obstructive/restrictive pattern (TLC , LLN).6 FRC may 
be increased above normal limits, due to static pulmonary 
hyperinflation.126 RV is likely to be above normal limits, due 
to premature airway closure during forced expiration.58,137 
TLC, FRC, and RV are expected to increase progressively 
with advancement of the disease.138
Diffusing capacity (DLCO or TLCO)
The transfer factor of carbon monoxide (TL
CO
) or diffus-
ing capacity (DL
CO
)139 can be abnormal in smokers with 
otherwise-preserved lung function;80 in particular the carbon 
monoxide transfer coefficient140 is significantly correlated 
with the amount of emphysema in smokers. A low baseline 
carbon monoxide transfer coefficient is independently associ-
ated with more rapid progression of emphysema and airflow 
limitation in heavy smokers.141 TL
CO
 measurement can pro-
vide additional prognostic information in COPD patients 
on follow-up.142 Low DL
CO
 is a predictor of future airflow 
obstruction in smokers with normal spirometry.93
Cardiopulmonary exercise test
In an elegant series of studies, O’Donnell et al clearly showed 
that compared to a matched control group, COPD patients 
with mild airflow limitation13 during exercise:
•	 develop dynamic lung hyperinflation;89
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•	 can exhibit a significant degree of electromechanical 
uncoupling;92
•	 have high V
D
:V
T
, which is the most consistent gas-
exchange abnormality.91
Respiratory impedance
It has been shown that the impulse-oscillation system allows 
determination of respiratory impedance and frequency 
dependence of resistance and has the potential to detect lung 
pathology in patients with COPD earlier than spirometry.90 
Therefore, smokers with a diagnosis of COPD and mild 
airflow obstruction should be carefully studied to explain 
symptoms, when present, and to establish a time 0 (baseline) 
for follow-up.140,141
Follow-up
After the seminal study by Fletcher and Peto,33 the rate of 
FEV
1
 decline over time has been suggested as the milestone 
variable to assess the progressive loss of lung function in 
COPD. However, the most recent GOLD document suggests 
that symptoms and exacerbations are the crucial variables for 
follow-up, whereas lung function may not be needed.1 This 
concept, which makes the life of the busy clinician easier, 
might be appropriate for patients with the overt disease, but 
should not be applied to patients with mild airflow limitation 
whose symptoms are highly dependent on an active lifestyle, 
where exacerbations may be interpreted as common viral 
infections, as in the general population.
The physiologic drop in lung function found in otherwise-
healthy nonsmokers has been reported as up to 30 mL/
year, and is accelerated in smokers up to a mean 80 mL/
year.33 However, the trajectories leading to COPD include 
not only rapid FEV
1
 decline but also normal rate of decay 
with lower starting value, eg, due to childhood respiratory 
illness.38,143 A population-based study reported data over 11 
years of observation in subjects with respiratory symptoms 
and normal lung function and GOLD 1 or more.45 Over-
all, FEV
1
 decline was greater in GOLD 1 patients than in 
normal subjects, and within stage 1 it was greater in those 
with respiratory symptoms than without.45 This was associ-
ated with increased utilization of respiratory care resources 
and lower health-related quality of life;45 the asymptomatic 
GOLD 1 patients being similar to the reference group of 
normal subjects. This is consistent with the observation that 
symptoms of chronic bronchitis without airflow obstruction 
are a risk factor for the development of COPD.144
Thoracic CT has been used to investigate the small 
airways and the periphery of the lungs. Recent publications 
have shown that CT-assessed functional small-airway dis-
ease and emphysema are associated with FEV
1
 decline, but 
the association with functional airway disease has greatest 
importance in mild–moderate COPD, where the rate of FEV
1
 
decline is greatest.43,99 The COPDGene study showed that the 
rate of FEV
1
 decline was higher in GOLD 1 than GOLD 2 and 
above, and that it was fostered by severe exacerbations.47
All these data support the idea that repeated measure-
ments of FEV
1
 should be performed in the follow-up of 
patients with GOLD 1 COPD, particularly in subjects with 
respiratory symptoms and exacerbations. Clearly, CT is an 
excellent tool for research, but it cannot be proposed for 
clinical practice, at least at present.47,99,124
A few years ago, Macklem suggested a different per-
spective to look at the natural history of COPD.138 Rather 
than focusing on FEV
1
 decline, he pointed attention to the 
progressive rise in static lung volume, ie, lung hyperinfla-
tion.126 Due to the loss of lung elastic recoil and small-airway 
closure at higher volumes, RV, FRC, and TLC increase, 
while VC, FVC, and FEV
1
 decrease. The fall in VC (or 
FVC) brings to the drop in FEV
1
, according to the formula 
FEV
1
 = (FEV
1
:VC)/VC. Although specific research on the 
natural history of COPD patients with mild airflow limita-
tion is lacking, the analysis from Macklem suggests that the 
measurement of changes in lung volume might be convenient 
for assessing the evolution of COPD. In this respect, the 
Swedish study (SCAPIS),145 which showed that the FEV
1
:VC 
ratio is more sensitive than the FEV
1
:FVC ratio in detecting 
the spirometric abnormalities of COPD, has to be mentioned. 
That study concluded that the use of only FVC when assess-
ing airflow limitation may result in a considerable underdiag-
nosis of patients with mild airflow limitation.145 Therefore, 
once a diagnosis of COPD with mild airflow limitation is 
obtained, periodic spirometry can provide a simple and reli-
able parameter for follow-up of patients. In this connection, 
there are two factors to be considered. First, the history of 
either childhood or maternal asthma17,146,147 and early-life 
lower respiratory illness147 should be investigated carefully, 
particularly in never- or former-smoking subjects with mild 
but irreversible airflow limitation, as a risk factor for faster 
FEV
1
 decline in adulthood. Second, low FEV
1
 in early adult-
hood may lead to COPD without an accelerated decline in 
FEV
1
.143 This emphasizes the need for more extensive use 
of spirometry early in life to disclose susceptible smokers, 
rapid FEV
1
 decliners (about 50 mL/year), or normal FEV
1
 
decliners (,30 mL/year) starting from low FEV
1
.
Therefore, we support the idea that lung function should be 
measured for the follow-up of patients with GOLD 1 COPD. 
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At present, the decision on the timing of measurement remains 
completely discretionary. It may depend upon the intensity of 
symptoms and exacerbations, age, and history of smoking, 
for example. Spirometry might be scheduled from 6 months 
to 2 years, according to the individual evaluation.
Future research
Many patients who meet the spirometric criteria of GOLD 
1 COPD are asymptomatic at rest and at moderate levels of 
exercise. The immediate consequence of this fact is that it is 
not known to a great extent what the natural history of this 
COPD subtype and its specific treatment are. In our opinion, 
there is a need for future research in the following areas 
in COPD patients with mild airflow limitation.
Diagnosis
Undiagnosed COPD is associated with increased health care 
costs and more cardiovascular risk factors.148,149 Although 
undiagnosed subjects appeared healthier than those with a 
diagnosis, their risk of death was increased compared with 
subjects without obstruction.150 At present, we do not know 
the prevalence or outcomes of COPD with mild airflow 
limitation based on the LLN. Neither do we know if a change 
in the diagnosis of mild airflow limitation based on such 
criteria as the LLN and/or GLI Z-scores could be associated 
with a different clinical presentation. We propose the fol-
lowing initiatives:
•	 studies to compare prevalence, clinical presentation, 
and outcomes among individuals diagnosed with mild 
airflow limitation on the basis of FEV
1
:FVC ,0.70 with 
those among individuals diagnosed on the basis of FEV
1
: 
FVC , LLN or even FEV
1
:VC , LLN;
•	 longitudinal studies addressing the GLI approach, using 
GLI prediction equations and FEV
1
 Z-scores to delineate 
severity grades;
•	 studies to investigate whether measurements of lung 
volume add valuable information for the diagnosis of 
COPD when airflow limitation is classified as mild;
•	 studies to evaluate the impact of the diagnosis of COPD 
with mild airflow limitation among younger versus older 
individuals (ie, is it more important to general health to 
diagnose asymptomatic or paucisymptomatic GOLD 1 
COPD in a 50-year-old than an 80-year-old?).
Clinical assessment
Most but not all COPD patients with mild airflow limitation 
are either current or ex-smokers with at least 10 pack-years 
of smoking history. At a primary care office, over a third of 
ex- and current smokers who were diagnosed with GOLD stage 
1 COPD based on screening spirometry were asymptomatic 
at the time of testing.151 As such, any current or ex-smokers 
should be tested with spirometry, regardless of the presence 
of respiratory symptoms.152 The question remains as to what 
else to perform after COPD with mild airflow limitation has 
been diagnosed. Of course, a minimum of anthropometric 
measurements and chest X-ray must be obtained. However, 
further research is needed to determine:
•	 the role of DL
CO
 and/or oscillatory resistance, and CT 
to identify subgroups of patients (phenotypes) with dif-
ferent clinical presentation and differential responses to 
treatment;
•	 whether different available indices of symptoms (eg, 
CAT), disease severity (ie, BODE index), coexistence 
comorbidities (ie, asthma, COTE index) or other mea-
sures (eg, lung function, CT findings, biomarkers) are 
useful surrogate markers of short-, medium-, or long-term 
patient-centered outcomes.
Treatment
It is believed that hospitalizations and deaths are relatively 
infrequent in COPD patients with mild airflow limitation. 
However, the information available is old and scarce.134 As in 
the rest of COPD patients, treatment goals should be focused 
on: 1) relieving patient symptoms, 2) slowing the progression 
of disease, and 3) mitigating the risk of the leading causes 
of hospitalization and mortality (cardiovascular disease and 
lung cancer). There is a need for:
•	 studies to clarify the appropriate approach and strategy 
to achieve abstinence from smoking (value to spirometry 
results, ie, effectiveness of pharmacological agents);
•	 pharmacological trials to analyze outcomes among GOLD 
stage 1 COPD subtypes (ie, current vs ex-smokers with 
or without coexistent asthma); it might be of interest to 
investigate whether long-acting bronchodilators, in par-
ticular antimuscarinic agents, anti-inflammatory drugs, 
or the combination of inhaled corticosteroids/long-acting 
β
2
-agonists can provide more benefits in the early stage 
of the disease, rather than in the most advanced ones;
•	 different end points might be considered to assess the effec-
tiveness of pharmacologic treatment, such as lung-function 
tests more closely related to the periphery of the lungs (RV, 
diffusion capacity, exercise tolerance) than FEV
1
 decline, 
and relevant clinical outcomes, such as exacerbations;
•	 nonpharmacological trials (ie, rehabilitation and encour-
agement of active lifestyle plus smoking-cessation 
intervention);
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•	 real-life observational studies to assess advantages/
disadvantages of being treated with different therapeutic 
approaches (eg, risk of pneumonia [Does early interven-
tion reduce disease progression?]).
Conclusion
It has been known for many years that significant pathophysi-
ologic abnormalities can be detected in smokers with normal 
spirometry. Furthermore, recent data show that smokers 
can report respiratory symptoms and seek medication with 
spirometric values still within normal limits. These two 
pieces of information suggest that “mild” airflow limitation, 
in smokers at least, can reflect well-established disease and 
not just a negligible insult of an otherwise-sufficient health 
status. These patients should be encouraged to pursue an 
active life style, which is not only healthy but also unravels 
the reduced exercise tolerance and may support any smoking-
cessation program.
A diagnosis of COPD with mild airflow limitation helps 
in recognizing and adequately treating exacerbations that 
might otherwise be interpreted differently and underesti-
mated. Finally, a follow-up program should be planned, both 
to understand whether “mild” is really “early” and to take 
any measurement (nonpharmacologic and pharmacologic) 
to prevent the progressive deterioration of health status. 
On one hand, any smoker or ex-smoker should undergo 
spirometry early in her/his health file; on the other hand, 
acute episodes should be regarded as possible exacerbations 
of undiagnosed COPD.
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Supplementary materials
In Slovenia, the National Institute of Public Health (NIJZ) is 
a state institution that reports on the prevalence of diseases 
at a national level. In Tables S1–S3, the data from year 2008 
are presented in a small region of northern Slovenia (with 
prevalence of smoking, above average Slovenian level). 
The striking finding is the high prevalence of smoking in 
younger adults, which is increasing mostly in young women. 
The overall prevalence of COPD in that region is 5.7% and 
in smokers 16.6%.
Table SI Smoking exposure and COPD prevalence from the year 2008
Smoking exposure in the general population
Current smokers by age groups and gender, year 2008 
(estimation on sample size 7,706)
Past smokers by age groups and gender, year 2008 
(estimation on sample size 7,706)
Age group Men (%) Women (%) Total (%) Age group Men (%) Women (%) Total (%)
25–29 26.3 19.4 22.3 25–29 14.2 21.4 18.6
30–34 27.5 15.6 20.5 30–34 23.1 19.3 20.8
35–39 25.0 17.8 20.5 35–39 19.7 18.2 18.8
40–44 28.5 22.9 25.3 40–44 27.5 26.9 27.1
45–49 22.9 20.8 21.7 45–49 38.1 24.3 30.1
50–54 22.4 17.6 19.6 50–54 40.4 24.9 31.3
55–59 17.8 14.3 15.8 55–59 43.2 22.6 32.0
60–64 12.6 8.7 10.4 60–64 44.7 17.9 30.0
65–69 7.7 4.8 6.2 65–69 35.1 13.5 23.5
70–74 7.2 3.5 5.2 70–74 40.2 12.3 25.3
Total 19.33 14.73 16.65 Total 33.19 20.19 25.67
Notes: Sourced from Cindi health monitor survey, 2008. University Clinic Respiratory and Allergic Diseases, Golnik, Slovenia.2
Table S2 Hospital admissions in the year 2007
Prevalence of COPD in current smokers is 16.6%
Age group
40–75 years
5.7% prevalence 
of COPD
Number of 
hospitalizations
Proportion of individuals 
having COPD and admitted 
to hospital (%)
518,783 29,570 2,391 8.1
Note: Sourced from Institute for Public Health of Slovenia, Ljublijana, In-patient Statistics Database University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, 
Estimation based on a survey focused on COPD Epidemiology within Pomurje Region, year 2006, sample size 2000, author Simona Slaček, General Hospital Murska 
Sobota.3
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Table S4 describes the trend of self-reported diagnosis 
of either asthma or chronic bronchitis (including COPD) 
in 2014 compared to 2007 in Slovenia. All answers of yes 
were supplemented by a doctor’s confirmation of diagnosis. 
Ten-year groups were created in the report of prevalence. 
The decrease in prevalence of both conditions is seen in the 
7-year period.
Table S4 Prevalence of the disease
EHIS 2014 Total Sex Age groups (years)
Did you have (in the last 12 months)... M F 15–24 25–34 35–44 45–54 55–64 65–74 75–84 85+
Asthma 88,456 40,357 48,099 10,405 8,449 14,112 15,917 12,687 11,387 11,581 3,919
Chronic bronchitis, COPD, emphysema 72,051 34,770 37,281 3,266 6,405 6,852 10,712 16,486 12,820 10,357 5,153
EHIS 2007 Total Sex Age groups (years)
Do you have or have you ever had... M F 15–24 25–34 35–44 45–54 55–64 65–74 75+
Asthma 104,016 53,914 50,102 21,352 17,099 7,150 17,229 8,803 17,703 14,680
Chronic bronchitis, COPD, emphysema 106,328 50,038 56,289 8,095 15,416 10,829 18,755 16,172 15,317 21,744
Comment: Those who answered positive for any of the above diagnoses were additionally asked whether the diagnosis had been confirmed by a doctor
EHIS 2007 Total Sex Age groups (years)
Has the diagnosis been confirmed 
by a doctor?
M F 15–24 25–34 35–44 45–54 55–64 65–74 75+
Asthma 100,053 51,610 48,443 20,746 16,764 7,150 17,229 8,803 14,682 14,680
Chronic bronchitis, COPD, emphysema 101,535 46,341 55,193 7,218 15,416 10,829 17,950 14,157 15,317 20,648
Comment: Those who answered positive for any of the above diagnoses, which were confirmed by a doctor, were additionally asked whether they 
had the disease in the last 12 months
EHIS 2007 Total Sex Age groups (years)
Did you have the disease in the last 12 months? M F 15–24 25–34 35–44 45–54 55–64 65–74 75+
Asthma 60,091 31,347 28,743 7,835 6,947 4,271 12,256 8,032 11,957 8,793
Chronic bronchitis, COPD, emphysema 54,039 19,768 34,271 393 4,271 3,946 11,853 8,750 9,742 15,085
Notes: Residents of Slovenia (age .15 years). From European Health Interview Surveys on health and health care, 2007 (EHIS 2007) and 2014 (EHIS 2014).1
Abbreviations: M, male; F, female; eHIS, european Health Interview Survey.
Table S3 Hospitalization costs in the year 2007
International 
Classification of 
Diseases (ICD)
Number 
of cases
DRG 
Weight
Average 
length of stay 
(days)
Costs in 
Euros per one 
hospitalization
Cost in Euros for 
hospitalization of all patients 
in certain ICD group
J40 38 1.05 5.03 1,322.475 50,254
J410 21 2.14 6.53 2,695.33 56,602
J411 18 1.62 13.44 2,040.39 36,727
J42 11 3.50 8.64 4,408.25 48,491
J438 27 1.79 6.75 2,254.505 60,872
J439 14 1.57 8.46 1,977.415 27,684
J440 792 1.99 11.23 2,506.405 1,985,073
J441 769 1.78 10.33 2,241.91 1,724,029
J448 201 1.65 9.04 2,078.175 417,713
J449 387 1.63 8.96 2,052.985 794,505
J47 113 1.66 10.11 2,090.77 236,257
Total 2,391 10.13 5,438,206
Notes: Sourced from Institute for Public Health of Slovenia, Ljublijana, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia. Cost estimation calculation 
factor based on ICD code.1
Abbreviation: DRG, diagnose related group.
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